<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00206076</url>
  </required_header>
  <id_info>
    <org_study_id>CEL350</org_study_id>
    <nct_id>NCT00206076</nct_id>
  </id_info>
  <brief_title>Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation</brief_title>
  <official_title>CellCept (Mycophenolate Mofetil, MMF) Maintenance Immunosuppression in Liver Transplant Recipients With Long-term Follow-up Post-transplantation for Non-Autoimmune Liver Disease - A Prospective, Randomized, Multicenter Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein Healthcare Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein Healthcare Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and efficacy of mycophenolate mofetil alone,
      or with reduced dose cyclosporine (CsA) or tacrolimus, for immunosuppression long-term after
      liver transplantation, in an attempt to reduce the potential side effects from using
      cyclosporine or tacrolimus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most liver transplant recipients receive an immunosuppressive drug regimen that contains
      either cyclosporine or tacrolimus. Although these drugs have revolutionized transplantation,
      in many patients their long-term use is a major cause of serious side effects, including
      kidney failure, hypertension, diabetes mellitus, hyperlipidemia, and/or neurologic side
      effects. Stopping or reducing the dose of cyclosporine or tacrolimus can ameliorate the above
      side effects but may increase the risk of rejection. Mycophenolate mofetil (MMF), a safe and
      effective immunosuppressant that does not cause the above side effects, is typically used in
      combination with cyclosporine or tacrolimus. Attempts in liver transplant recipients at using
      mycophenolate mofetil alone or with reduced dose cyclosporine or tacrolimus have been
      successful but some patients developed rejection, and a few patients suffered liver failure.
      Most rejections after liver transplantation are easy to successfully treat with increased
      immunosuppression, but such treatment may carry risks such as increased susceptibility to
      infection. There have not yet been any large trials to adequately assess the safety and
      efficacy of using mycophenolate mofetil this way (alone or with reduced dose calcineurin
      inhibitor (CNI)).

      The purpose of this trial is to evaluate whether mycophenolate mofetil as monotherapy or with
      reduced dose cyclosporine or tacrolimus long-term after liver transplantation is safe and
      decreases side effects related to calcineurin inhibitor use.

      Only liver recipients expected to have a relatively low risk of developing rejection and/or
      liver failure are eligible for this trial. Some reasons for considering them low risk are
      their stable liver function, having had the transplant for over a year, having had one or
      fewer prior rejection episodes, having had non-autoimmune liver disease, their currently
      requiring low dose/level cyclosporine or tacrolimus, and the plan to use high dose
      mycophenolate mofetil and to exclude patients that fail to attain target values for
      mycophenolic acid area under the concentration-time curve (MPA AUC - MycoPhenolic Acid Area
      Under the Curve).

      Eligible patients will be randomized to receive either mycophenolate mofetil monotherapy
      (MMF; CNI discontinued), or mycophenolate mofetil and half their baseline dose of calcineurin
      inhibitor (MMF; CNI decreased). The primary outcome is biopsy proven rejection and the
      secondary outcomes include patient and graft survival, adverse events, hepatic profile, blood
      pressure, renal function, diabetes, and lipid profile. Additionally, mycophenolic acid
      concentrations will be measured; a mycophenolate mofetil monotherapy trial provides unique
      opportunity to study the implications of such monitoring. Patients will be followed for 12
      months; there will be 16 visits during the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Biopsy Proven Rejections at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>assessed by liver biopsy using Banff International Consensus Schema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient and Graft Survival at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Including Infections at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mycophenolate mofetil monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mycophenolate mofetil and half their baseline dose of calcineurin inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>mycophenolate mofetil and half their baseline dose of calcineurin inhibitor</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>mycophenolate mofetil monotherapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 years of age or older (females who can become pregnant must use two
             acceptable methods of birth control while taking mycophenolate mofetil)

          -  Orthotopic liver transplant more than one year prior to enrollment

          -  Using calcineurin inhibitor to prevent rejection at time of screening

          -  Patients must be willing to provide informed consent and abide by the requirements of
             the study

        Exclusion Criteria:

          -  Liver disease may not have been secondary to an autoimmune cause, including:

               -  autoimmune hepatitis,

               -  primary sclerosing cholangitis,

               -  primary biliary cirrhosis

          -  Patients who have had:

               -  more than one prior episode of rejection,

               -  rejection within the past six months,

               -  any corticosteroid resistant rejection

          -  Patients with a tacrolimus trough level of greater than 7 ng/ml within 90 days prior
             to enrollment

          -  Patients with a cyclosporine trough level greater than 225 ng/ml within 90 days prior
             to enrollment

          -  Patients taking more the 5 mg per day of prednisone within 90 days prior to enrollment

          -  Patients taking any prednisone within 30 days of enrollment

          -  Allograft dysfunction within 6 months of enrollment, including ALT and/or total
             bilirubin greater than 2x normal, and/or biopsy proven hepatitis C virus (HCV) with
             fibrosis greater than stage II

          -  White blood cell count less than 2,500 or platelet count less than 50,000 within 60
             days of enrollment

          -  MPA AUC threshold: Patients are not eligible for the study if they do not attain the
             threshold value MPA AUC (&gt;30 mg*h/L if on CsA, &gt;40 mg*h/L if on tacrolimus) after 50%
             calcineurin inhibitor reduction, measured using a 3-sample estimate (trough, 30-min,
             120-min)

          -  Patients who have had a previous transplant of organ(s) other than liver

          -  Patients who received a liver from a hepatitis C positive donor

          -  Patients who received a liver from a living donor

          -  Patients with any technical complication requiring intervention within the three
             months prior to screening

          -  Current infection requiring treatment

          -  History of post transplant lymphoproliferative disorder

          -  History of malignancy other than non-melanoma skin cancer or Stage 1-2 hepatoma

          -  Active or unhealed duodenal ulcer

          -  Concomitant treatment with rapamycin and/or interferon

          -  Known allergy or sensitivity to CellCept® or any of its components

          -  Unable or unwilling to comply with the protocol requirements or considered by the
             investigator(s) to be unfit for the study

          -  Participation in a clinical trial within 30 days prior to study entry or prior
             enrollment in any CellCept® clinical trial

          -  Pregnant or breastfeeding woman

          -  Diabetes with known, clinically significant gastroparesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Reich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drexel College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky at Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Reich DJ, Clavien PA, Hodge EE; MMF Renal Dysfunction after Liver Transplantation Working Group. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation. 2005 Jul 15;80(1):18-25.</citation>
    <PMID>16003228</PMID>
  </reference>
  <reference>
    <citation>Reich D, Rothstein K, Manzarbeitia C, Muñoz S. Common medical diseases after liver transplantation. Semin Gastrointest Dis. 1998 Jul;9(3):110-25. Review.</citation>
    <PMID>9700842</PMID>
  </reference>
  <reference>
    <citation>Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W, McMichael J, Fung JJ, Starzl TE. Weaning of immunosuppression in liver transplant recipients. Transplantation. 1997 Jan 27;63(2):243-9.</citation>
    <PMID>9020325</PMID>
  </reference>
  <reference>
    <citation>McDiarmid SV, Farmer DA, Goldstein LI, Martin P, Vargas J, Tipton JR, Simmons F, Busuttil RW. A randomized prospective trial of steroid withdrawal after liver transplantation. Transplantation. 1995 Dec 27;60(12):1443-50.</citation>
    <PMID>8545872</PMID>
  </reference>
  <reference>
    <citation>Fraser GM, Grammoustianos K, Reddy J, Rolles K, Davidson B, Burroughs AK. Long-term immunosuppression without corticosteroids after orthotopic liver transplantation: a positive therapeutic aim. Liver Transpl Surg. 1996 Nov;2(6):411-7.</citation>
    <PMID>9346686</PMID>
  </reference>
  <reference>
    <citation>Stegall MD, Everson GT, Schroter G, Karrer F, Bilir B, Sternberg T, Shrestha R, Wachs M, Kam I. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology. 1997 Jan;25(1):173-7.</citation>
    <PMID>8985286</PMID>
  </reference>
  <reference>
    <citation>Hodge EE, Reich DJ, Clavien PA, Kim-Schluger L. Use of mycophenolate mofetil in liver transplant recipients experiencing renal dysfunction on cyclosporine or tacrolimus-randomized, prospective, multicenter study results. Transplant Proc. 2002 Aug;34(5):1546-7.</citation>
    <PMID>12176477</PMID>
  </reference>
  <reference>
    <citation>Raimondo ML, Dagher L, Papatheodoridis GV, Rolando N, Patch DW, Davidson BR, Rolles K, Burroughs AK. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation. 2003 Jan 27;75(2):186-90.</citation>
    <PMID>12548120</PMID>
  </reference>
  <reference>
    <citation>Schlitt HJ, Barkmann A, Böker KH, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet. 2001 Feb 24;357(9256):587-91.</citation>
    <PMID>11558484</PMID>
  </reference>
  <reference>
    <citation>Herrero JI, Quiroga J, Sangro B, Girala M, Gómez-Manero N, Pardo F, Alvárez-Cienfuegos J, Prieto J. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg. 1999 Sep;5(5):414-20.</citation>
    <PMID>10477843</PMID>
  </reference>
  <reference>
    <citation>Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet. 2001 Feb 24;357(9256):609-10.</citation>
    <PMID>11558493</PMID>
  </reference>
  <reference>
    <citation>Munoz SJ, Rothstein KD, Reich D, Manzarbeitia C. Long-term care of the liver transplant recipient. Clin Liver Dis. 2000 Aug;4(3):691-710. Review.</citation>
    <PMID>11232168</PMID>
  </reference>
  <reference>
    <citation>Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, McMaster P, Kalayoglu M, Levy G, Freeman R, Bismuth H, Neuhaus P, Mamelok R, Wang W. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl. 2001 May;7(5):442-50.</citation>
    <PMID>11349266</PMID>
  </reference>
  <reference>
    <citation>Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003 May;3(5):534-42. Review.</citation>
    <PMID>12752309</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>February 23, 2012</results_first_submitted>
  <results_first_submitted_qc>July 31, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 2, 2013</results_first_posted>
  <last_update_submitted>July 31, 2013</last_update_submitted>
  <last_update_submitted_qc>July 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver transplantation</keyword>
  <keyword>Calcineurin inhibitor withdraw</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <keyword>Immunosuppression side effects</keyword>
  <keyword>Graft rejection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were current patients from 3 outpatient transplant offices and recruited between July 2006 and May 2008.</recruitment_details>
      <pre_assignment_details>Participants were screened over a 2 week period. Three participants withdrew consent after signing the consent form. One participant failed screening (didn't attain threshold MPA level). These subjects were excluded from the trial before assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MMF, CNI Discontinued</title>
          <description>Received Mycophenolate Mofetil (MMF); Complete withdrawal of calcineurin inhibitors (CNI)</description>
        </group>
        <group group_id="P2">
          <title>MMF; CNI Decreased</title>
          <description>Received Mycophenolate Mofetil (MMF); calcineurin inhibitors (CNI) decreased to 50% of pre-enrollment dosage</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MMF, CNI Discontinued</title>
          <description>Received Mycophenolate Mofetil (MMF); Complete withdrawal of calcineurin inhibitors (CNI)</description>
        </group>
        <group group_id="B2">
          <title>MMF; CNI Decreased</title>
          <description>Received Mycophenolate Mofetil (MMF); calcineurin inhibitors (CNI) decreased to 50% of pre-enrollment dosage</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.11" spread="8.46"/>
                    <measurement group_id="B2" value="54.6" spread="7.26"/>
                    <measurement group_id="B3" value="55.32" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Biopsy Proven Rejections at 12 Months</title>
        <description>assessed by liver biopsy using Banff International Consensus Schema</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MMF, CNI Discontinued</title>
            <description>Received Mycophenolate Mofetil (MMF); Complete withdrawal of calcineurin inhibitors (CNI)</description>
          </group>
          <group group_id="O2">
            <title>MMF; CNI Decreased</title>
            <description>Received Mycophenolate Mofetil (MMF); calcineurin inhibitors (CNI) decreased to 50% of pre-enrollment dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Biopsy Proven Rejections at 12 Months</title>
          <description>assessed by liver biopsy using Banff International Consensus Schema</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient and Graft Survival at 12 Months</title>
        <time_frame>12 months</time_frame>
        <population>everyone enrolled who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>CNI Discontinued</title>
            <description>complete withdrawal of calcineurin inhibitors (CNI)</description>
          </group>
          <group group_id="O2">
            <title>CNI Reduction</title>
            <description>calcineurin inhibitors (CNI) decreased to 50% of pre-enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Patient and Graft Survival at 12 Months</title>
          <population>everyone enrolled who completed the study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Including Infections at 12 Months</title>
        <time_frame>12 months</time_frame>
        <population>everyone enrolled who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>MMF, CNI Discontinued</title>
            <description>Received Mycophenolate Mofetil (MMF); Complete withdrawal of calcineurin inhibitors (CNI)</description>
          </group>
          <group group_id="O2">
            <title>MMF; CNI Decreased</title>
            <description>Received Mycophenolate Mofetil (MMF); calcineurin inhibitors (CNI) decreased to 50% of pre-enrollment dosage</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Including Infections at 12 Months</title>
          <population>everyone enrolled who completed the study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MMF, CNI Discontinued</title>
          <description>Received Mycophenolate Mofetil (MMF); Complete withdrawal of calcineurin inhibitors (CNI)</description>
        </group>
        <group group_id="E2">
          <title>MMF; CNI Decreased</title>
          <description>Received Mycophenolate Mofetil (MMF); calcineurin inhibitors (CNI) decreased to 50% of pre-enrollment dosage</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>change in white blood cell count</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation alter with diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased liver enzymes</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Reich, MD</name_or_title>
      <organization>Drexel University College of Medicine</organization>
      <phone>215-762-7143</phone>
      <email>David.Reich@DrexelMed.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

